Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2022

View Archived Issues

SIGLEC15 promotes immune system evasion in lymphoma

TL-532 induces life-long antitumor autovaccination and cross-immunity against unrelated cancers

Rheinische Friederich-Wilhelms-Universitaet Bonn discloses MRGPRX4 agonists

Chinese researchers describe new ADCs for cancer

Proxygen and collaborators present new compounds for cancer

AC Immune synthesizes MAPT aggregation inhibitors

Accent Therapeutics discloses METTL3 inhibitors

Targeting BCL10-MALT1 interaction blocks ABC-DLBCL xenograft tumor growth

Type 2 diabetes getting precision medicine makeover

MALT1 promotes glioblastoma pathogenesis and emerges as a potential therapeutic target

Celsion advances PLACCINE DNA-based vaccine platform to proof-of-concept NHP studies

NexImmune, Yale and JDRF partner to explore AIM nanoparticles with teplizumab for type 1 diabetes

NodThera announces addition of third NLRP3 inflammasome inhibitor to pipeline

Incannex's IHL-216A shows neuroprotective effect in rodent model of sports concussion

Galectin-8 as a novel target for the treatment of bacterial keratitis

Investigators present new murine model of Kcnv2-mutated CDSRR

Long noncoding RNA LOC100506453 found as useful for treatment monitoring in APL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...